Han et al. demonstrated that EGFR-TKIs could activate cell autophagy to impair the sensitivity of lung cancer cells to targeted therapy by inhibiting the AKT-mTOR-p70S6K signaling pathway 41. This evidence concerns the gene AKT1 and lung cancer.